The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: pharmacologic rationale and results of clinical trials.
D000005:Abdomen; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002460:Cell Line; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007700:Kinetics; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010146:Pain; D010529:Peritoneal Cavity; D010538:Peritonitis / Q000209:etiology; D010994:Pleura; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine; D004317:Doxorubicin; D002945:Cisplatin